Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
| dc.contributor.author | Rodgers, Helen | |
| dc.contributor.author | Shaw, Lisa | |
| dc.contributor.author | Price, Christopher | |
| dc.contributor.author | van Wijck, Frederike | |
| dc.contributor.author | Barnes, Michael | |
| dc.contributor.author | Graham, Laura | |
| dc.contributor.author | Ford, Gary | |
| dc.contributor.author | Shackley, Phil | |
| dc.contributor.author | Steen, Nick | |
| dc.contributor.author | BoTULS investigators, On behalf of | |
| dc.date.accessioned | 2018-06-29T21:44:39Z | |
| dc.date.available | 2018-06-29T21:44:39Z | |
| dc.date.issued | 2008-10 | |
| dc.description | Funding National Institute for Health Research, Health Technology Assessment Programme. Ipsen Ltd provide botulinum toxin type A (Dysport). | |
| dc.description.abstract | Background Following a stroke, 55-75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear. The aim of this study is to evaluate the clinical and cost effectiveness of botulinum toxin type A plus an upper limb therapy programme in the treatment of post stroke upper limb spasticity. Methods Trial design : A multi-centre open label parallel group randomised controlled trial and economic evaluation. Participants : Adults with upper limb spasticity at the shoulder, elbow, wrist or hand and reduced upper limb function due to stroke more than 1 month previously. Interventions : Botulinum toxin type A plus upper limb therapy (intervention group) or upper limb therapy alone (control group). Outcomes : Outcome assessments are undertaken at 1, 3 and 12 months. The primary outcome is upper limb function one month after study entry measured by the Action Research Arm Test (ARAT). Secondary outcomes include: spasticity (Modified Ashworth Scale); grip strength; dexterity (Nine Hole Peg Test); disability (Barthel Activities of Daily Living Index); quality of life (Stroke Impact Scale, Euroqol EQ-5D) and attainment of patient-selected goals (Canadian Occupational Performance Measure). Health and social services resource use, adverse events, use of other antispasticity treatments and patient views on the treatment will be compared. Participants are clinically reassessed at 3, 6 and 9 months to determine the need for repeat botulinum toxin type A and/or therapy. Randomisation : A web based central independent randomisation service. Blinding : Outcome assessments are undertaken by an assessor who is blinded to the randomisation group. Sample size : 332 participants provide 80% power to detect a 15% difference in treatment successes between intervention and control groups. Treatment success is defined as improvement of 3 points for those with a baseline ARAT of 0-3 and 6 points for those with ARAT of 4-56. | |
| dc.description.eprintid | 682 | |
| dc.description.faculty | sch_phy | |
| dc.description.ispublished | pub | |
| dc.description.number | 1 | |
| dc.description.referencetext | 1. Skilbeck CE, Wade DT, Langton-Hewer R, Wood VA: Recovery after stroke. Journal of Neurology, Neurosurgery and Psychiatry 1983, 46:5-8. 2. Heller A, Wade DT, Wood VA, Sunderland A, Langton-Hewer R, Ward E: Arm function after stroke: measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry 1987, 50(6):714-719. 3. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, Hermens H, Johnson GR: Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability & Rehabilitation 2005, 27:2-6. 4. Lance JW: Symposium Synopsis. In Spasticity: Disordered Motor Control Edited by: Feldman RG, Young RR, Koella WP. Chicago, London: Symposium Specialists Inc, Year Book Medical Publishers; 1980. 5. Royal College of Physicians: Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. 2002. 6. Barnes M, Bhakta B, Moore P, Richardson D, Salisbury C, Thornton H, Turner-Stokes L, Ward A: The management of adults with spasticity using botulinum toxin: a guide to clinical practice. Radius Healthcare, Surrey 2001. 7. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP: Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310. 8. Hesse S, Reiter F, Konrad M, Jahnke MT: Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double- blind, placebo-controlled trial. Clinical Rehabilitation 1998, 12:381-388. 9. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402-2406. 10. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo- controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 2000, 69:217-221. 11. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L: A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. European Journal of Neurology 2001, 8:559-565. 12. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee C, Jenkins S, Turkel C: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. New England Journal of Medicine 2002, 347:395-400. 13. Brashear A, McAfee AL, Kuhn ER, Fyffe J: Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebocontrolled trial. Archives of Physical Medicine & Rehabilitation 2004, 85:705-709. 14. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT: Dose-dependent response to intramuscular botulinum toxin type A for upperlimb spasticity in patients after a stroke. Archives of Physical Medicine & Rehabilitation 2004, 85:1063-1069. 15. Suputtitada A, Suwanwela NC: The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disability & Rehabilitation 2005, 27:176-184. 16. van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J: Treatment of upper extremity spasticity in stroke patients by focal neuro nal or neuromuscular blockade: a systematic review of the literature. Journal of Rehabilitation Medicine 2002, 34:51-61. 17. Cardoso E, Rodrigues B, Lucena R, Oliveira IRd, Pedreira G, Melo A: Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arquivos de Neuro-Psiquiatria 2005, 63:30-33. 18. Garces K, McCormick A, McGahan L, Skidmore B: Botulinum Toxin A for upper and lower limb spasticity: a systematic review [Technology report no 51] Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005. 19. Stroke Unit Trialists Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007:CD000197. 20. Lyle RC: A performance test for assessment of upper limb function in physical rehabilitation treatment and research. International Journal of Rehabilitation Research 1981, 4:483-492. 21. Demeurisse G, Demol O, Robaye E: Motor evaluation in vascular hemiplegia. European Neurology 1980, 19:382-389. 22. Sunderland A, Tinson D, Bradley L, Hewer RL: Arm function after stroke. An evaluation of grip strength as a measure of recovery and a prognostic indicator. J Neurol Neurosurg Psychiatry 1989, 52(11):1267-1272. 23. Sharpless JW: The nine hole peg test of finger hand coordination for the hemiplegic patient. In Mossman's A Problem Orientated Approach to Stroke Rehabilitation Second edition. Illinois: Charles C Thomas; 1982. 24. Bohannon RW, Smith MB: Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy 1987, 67:206-207. 25. Law M, Baptiste S, McColl M, Opzoomer A, Polatajko H, Pollock N: The Canadian Occupational Performance Measure: An Outcome Measure for Occupational Therapy. Canadian Journal of Occupational Therapy - Revue Canadienne d Ergotherapie 1990, 57:82-87. 26. Mahoney FI, Barthel DW: Functional Evaluation: the Barthel Index. Maryland State Medical Journal 1965, 14:61-65. 27. Duncan PW, Bode RK, Min Lai S, Perera S: Rasch analysis of a new stroke-specific outcome scale: the Stroke Impact Scale. Archives of Physical Medicine & Rehabilitation 2003, 84:950-963. 28. Euroquol Group: Euroquol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-290. 29. Price DD, Bush FM, Long S, Harkins SW: A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 1994, 56:217-226. 30. Hodkinson HM: Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing 1972, 1:233-239. 31. Al-Khawaja I, Wade DT, Collin CF: Bedside screening for aphasia: a comparison of two methods. Journal of Neurology 1996, 243:201-204. 32. Bamford JL, Sandercock PAG, Warlow CP, Slattery J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989, 20:828-844. 33. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337:1521-1526. 34. Royal College of Physicians: National clinical guidelines for stroke (second edition). 2004. 35. Wade D: Goal planning in stroke rehabilitation: evidence. Topics in Stroke Rehabilitation 1999, 6:37-42. 36. Pomeroy V, Tallis R: Restoring movement and functional ability after stroke: now and the future. Physiotherapy 2002, 88:3-17. 37. Lee JH van der, Snels IA, Beckerman H, Lankhorst GJ, Wagenaar RC, Bouter LM: Exercise therapy for arm function in stroke patients: a systematic review of randomized controlled trials. Clinical Rehabilitation 2001, 15:20-31. 38. Kwakkel G, Wagenaar R, Twisk J, Lankhorst G, Koetsier J: Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial. Lancet 1999, 354:191-196. 39. Dean CM, Richards CL, Malouin F: Task-related circuit training improves performance of locomotor tasks in chronic stroke: a randomized, controlled pilot trial. Archives of Physical Medicine & Rehabilitation 2000, 81:409-417. 40. Dean CM, Shepherd RB: Task-related training improves performance of seated reaching tasks after stroke. A randomized controlled trial. Stroke 1997, 28:722-728. 41. Carr J, Shepherd RB: Stroke Rehabilitation. Guidelines for exercise training to optimise motor skill London: Butterworth Heinemann; 2003. 42. Barnes MP, Johnson GR: Upper Motor Neurone Syndrome and Spasticity First edition. Cambridge: Cambridge University Press; 2001. 43. Barnes M, Dobkin B, Bogousslavsky J: Recovery after stroke Cambridge: Cambridge University Press; 2005. 44. Edwards S: Neurological Physiotherapy 2nd edition. Edinburgh: Churchill Livingstone; 2002. 45. Lannin NA, Herbert RD: Is hand splinting effective for adults following stroke? A systematic review and methodologic critique of published research. Clinical Rehabilitation 2003, 17:807-816. 46. Guidelines on Stroke [http://www.sign.ac.uk] 47. Stokes M: Physical Management in Neurological Rehabilitation 2nd edition. Edinburgh: Elsevier Mosby; 2005. 48. Van Peppen RPS, Kwakkel G, Wood-Dauphinee S, Hendriks HJM, Wees PJ Van der, Dekker J: The impact of physical therapy on functional outcomes after stroke: what's the evidence? Clinical Rehabilitation 2004, 18:833-862. 49. Hanlon RE: Motor learning following unilateral stroke. Archives of Physical Medicine & Rehabilitation 1996, 77:811-815. 50. Magill RA: Motor Learning: Concepts and Applications Boston: McGraw Hill; 2001. 51. Shea JB, Morgan RL: Contextual interference effects on the acquisition, retention and transfer of a motor skill. Journal of Experimental Psychology: Learning, Memory and Cognition 1979, 5:179-187. 52. Duncan PW: Synthesis of intervention trials to improve motor recovery following stroke. Topics in Stroke Rehabilitation 1997, 3:. 53. van Wijck F, Mackenzie J, Hooper J, Barnes M, Johnson G: Improving arm function in patients with chronic spasticity: combining botulinum toxin with a task orientated motor learning programme. International Journal of Rehabilitation Research 2004, 27(suppl 1):109. 54. Medicines for Human Use (Clinical Trials) Regulations 2004 [http://www.uk-legislation.hmso.gov.uk/si/si2004/20041031.htm] 55. Donaldson C, Shackley P: Economics evaluation 3rd edition. Oxford: Oxford University Press; 1997. 56. Drummond MF, O'Brien B, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care 2nd edition. Oxford: Oxford University Press; 1997. 57. Gold M, Siegel J, Russell L, Weinstein M: Cost effectiveness in health and medicine New York: Oxford University Press; 1996. 58. McNamee P, Christensen J, Soutter J, Rodgers H, Craig N, Pearson P, Bond J: Cost analysis of early supported hospital discharge for stroke. Age and Ageing 1998:345-351. 59. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MDM, Barer DH: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397. 60. Fleiss JL: Statistical Methods for Rates and Proportions New York: Wiley; 1981. 61. Pandyan AD, Vuadens P, van Wijck FMJ, Stark S, Johnson GR, Barnes MP: Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clinical Rehabilitation 2002, 16:654-660. 62. ICH Harmonised Tripartite Guideline for Good Clinical Practice [http://www.ich.org] 63. Department of Health: Research Governance Framework for Health and Social Care. Second edition. 2005. | |
| dc.description.status | pub | |
| dc.description.volume | 9 | |
| dc.format.extent | 59 | |
| dc.identifier | ER682 | |
| dc.identifier.citation | Rodgers, H., Shaw, L., Price, C., van Wijck, F., Barnes, M., Graham, L., Ford, G., Shackley, P., Steen, N., and BoTULS investigators (2008) ‘Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A’, Trials, 9(1), p. 59. Available at: https://doi.org/10.1186/1745-6215-9-59. | |
| dc.identifier.doi | http://doi:10.1186/1745-6215-9-59 | |
| dc.identifier.issn | 1745-6215 | |
| dc.identifier.uri | https://doi.org/10.1186/1745-6215-9-59 | |
| dc.identifier.uri | https://eresearch.qmu.ac.uk/handle/20.500.12289/682 | |
| dc.publisher | BioMed Central | |
| dc.relation.ispartof | Trials | |
| dc.title | Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A | |
| dc.type | article | |
| dcterms.accessRights | public | |
| qmu.author | van Wijck, Frederike | |
| rioxxterms.type | article |
Files
Original bundle
1 - 1 of 1